(TXG) 10X Genomics - Ratings and Ratios

10X Genomics Inc. (NASDAQ:TXG) is a leading life science technology company specializing in the development and commercialization of innovative instruments, consumables, and software for biological system analysis. The company operates globally, serving customers across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. Its product portfolio includes the Chromium platform, which enables single-cell and multiomic analysis through microfluidic chips, consumables, and instruments like the Chromium X Series. The Visium platform offers spatial gene expression and protein analysis solutions, including the Visium CytAssist instrument, which streamlines workflows for spatial biology applications. Additionally, the Xenium Analyzer allows researchers to detect RNA targets in fresh frozen or FFPE tissue sections while preserving cellular spatial information. The company serves a diverse range of customers, including academic institutions, government laboratories, and biopharmaceutical and biotechnology firms. Originally named 10X Technologies, Inc., the company rebranded as 10X Genomics Inc. in November 2014 and was incorporated in 2012. It is headquartered in Pleasanton, California.

From a technical perspective, TXG stock has shown declining momentum, with its SMA 20, 50, and 200 all below the last price of $8.43. This indicates bearish sentiment in the short to long term. The ATR of 0.63 reflects moderate volatility. Fundamentally, the company has a market cap of $997.39M, with a forward P/E of 196.08, suggesting high valuations relative to expected earnings. The P/B ratio of 1.47 indicates that the stock is trading at a premium to its book value. However, the negative RoE of -25.72% highlights ongoing profitability challenges.